News Column

Note 2 - Going Concern and Management Plans

August 14, 2014

As of June 30, 2014, the Company had a working capital deficiency and a stockholders' deficiency of $8,163,102 and $7,148,786, respectively. During the three and six months ended June 30, 2014, the Company incurred net losses of $1,333,139 and $3,002,815, respectively. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company's primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company's debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company's business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. 6 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 2 - Going Concern and Management Plans - Continued

Subsequent to June 30, 2014, the Company has raised an aggregate of $205,000 through equity financing, has received research and development payments of $89,063, has extended the due date for the repayment of $4,000,000 of debt, and $76,669 and $2,992 of debt and accrued interest, respectively, has been converted into common stock. As a result, the Company expects to be able to fund its operations through October 2014. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $244,063 which are either past due or payable on demand. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 8 - Subsequent Events for additional details.



Note 3 - Summary of Significant Accounting Policies

Principles of Consolidation



The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. ("Cayman") and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company's significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company's stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company's deferred tax assets. Certain of the Company's estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company's estimates and could cause actual results to differ from those estimates.



Concentrations and Credit Risk

As of June, 30 2014, approximately 75% of the face value of the Company's outstanding notes payable were received from a single entity (the "Bermuda Lender"). See Note 5 - Notes Payable for additional discussion of the Bermuda Lender.

Revenue Recognition



Research and Development Agreements

The Company's policy is to recognize research and development revenues on a straight-line basis over the term of the agreement, regardless of the payment structure, subject to potential acceleration upon achievement of contractually specified deliverables. On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 at commencement; (2) $50,000 upon achievement of a specified deliverable; and (3) $50,000 upon achievement of the final specified deliverable. As of June 30, 2014, the initial $150,000 payment had been received and $79,281 was recorded as deferred revenues on the condensed consolidated balance sheet. 7 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 3 - Summary of Significant Accounting Policies - Continued

Revenue Recognition - Continued

Research and Development Agreements - Continued

On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments, subject to acceleration upon achieving a specified deliverable. As of June 30, 2014, the initial $250,000 payment had been received and $145,694 was recorded as deferred revenues on the condensed consolidated balance sheet.

During the three and six months ended June 30, 2014, the Company recognized revenue related to research and development agreements of $175,025. The Company did not recognize any revenue related to research and development agreements during the three and six months ended June 30, 2013. Other The Company's policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.

During the three and six months ended June 30, 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $916 and $1,291, respectively. During the three and six months ended June 30, 2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $425 and $1,555, respectively.



Net Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2014 2013 Options 8,709,000 3,963,000 Warrants 6,325,751 4,370,890 Convertible notes 1,482,093 -



Total potentially dilutive shares 16,516,844 8,333,890

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company's 2010 Equity Participation Plan (the "Plan") were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company's restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted

to employees. 8 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 3 - Summary of Significant Accounting Policies - Continued

Convertible Instruments GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.



Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers," ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its condensed consolidated financial position and results of operations. In June 2014, the FASB issued ASU No. 2014-10, "Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation," ("ASU 2014-10"). ASU 2014-10 removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders' equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt ASU 2014-10 effective with this Quarterly Report on Form 10-Q and its adoption resulted in the removal of previously required development stage disclosures. The Company's planned principal operations are to develop technology using cell and tissue regenerative therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company is currently seeking to establish a new laboratory facility and increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company's activities are subject to significant risks and uncertainties, which are detailed in Note 2 - Going Concern and Management's Plans. 9 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 3 - Summary of Significant Accounting Policies - Continued

Recently Issued Accounting Pronouncements

In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its condensed consolidated financial statements.



Note 4 - Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities are comprised of the following: June 30, December 31, 2014 2013 (unaudited) Credit card payable $ 4,772$ 6,000 Accrued payroll and payroll taxes 757,205 672,535 Other accrued expenses 393,989 495,817 Deferred rent - 2,310 Total $ 1,155,966$ 1,176,662 During the six months ended June 30, 2014, the Company received an aggregate of $15,015 in non-interest bearing advances from an officer of the Company and made aggregate repayments to a director and a family member of an officer of $40,005 of advances (plus accrued interest), such that the Company had no remaining liability at June 30, 2014. During the six months ended June 30, 2013, the Company received an aggregate of $75,385 in non-interest bearing advances from a director and an officer of the Company and made aggregate repayments of $69,370 of advances, such that the Company had a liability to the officer of $6,015 at June 30, 2013, which was due on demand. 10 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited) Note 5 - Notes Payable A summary of the notes payable activity during the six months ended June 30, 2014 is presented below: Bermuda Convertible Other Debt Lender Notes Notes Discount Total Outstanding, December 31, 2013 $ 4,000,000$ 281,000$ 1,473,500$ (240,491 )$ 5,514,009 Issuances 500,000 175,000 [1] - - 675,000 Exchanges for equity - (71,000 ) (203,000 ) - (274,000 ) Conversions to equity - (157,081 ) - - (157,081 ) Repayments - - (53,000 ) - (53,000 ) Setup of debt discount - - - (61,384 ) (61,384 ) Amortization of debt discount - - - 244,435 244,435 Accretion of interest expense - 11,250 [2] 73,058 [3] 9,934 [1] 94,242 Outstanding, June 30, 2014 $ 4,500,000$ 239,169 [4]

$ 1,290,558$ (47,506 )$ 5,982,221



[1] On March 10, 2014, a note with a principal amount of $30,000 was issued for

cash consideration of $25,000 and bears no interest. The $5,000 difference

was recorded as debt discount and will be accreted as interest expense over

the term of the note. During the six months ended June 30, 2014, the Company

accreted interest expense of $9,934 related to notes issued for cash consideration less than the principal amounts.



[2] During the six months ended June 30, 2014, pursuant to the terms of certain

notes payable with maturity dates ranging from January 8, 2014 to March 18,

2014, the principal balances of the notes were increased from an aggregate of

$60,000 to $71,250. The aggregate $11,250 of principal increases was accreted

as interest expense.



[3] On April 1, 2014, in connection with the extension of certain notes payable

with maturity dates ranging from August 8, 2013 to December 6, 2013 to new

maturity dates ranging from October 1, 2014 to April 1, 2015, an aggregate of

$73,058 of accrued interest was added to the principal balance of the notes,

increasing the aggregate principal balance from $652,500 to $725,558.



[4] As of June 30, 2014, a Convertible Note with a principal balance of $26,669

was convertible at the election of the holder.

On May 8, 2014, Cayman issued the Bermuda Lender a one-year note payable in the principal amount of $500,000 which bears interest at 15% per annum payable at maturity. The note also provides for the mandatory prepayment of the principal amount to the extent of any monies received by the Company pursuant to the research and development agreements discussed in Note 3 - Summary of Significant Accounting Policies - Revenue Recognition - Research and Development Agreements. Interest on the entire principal amount of the note is payable until such time as the principal amount is paid in full. See Note 8 - Subsequent Events for details regarding maturity extensions and monies received pursuant to the research and development agreements. As of the filing date of this report, 76% of the face value of the Company's outstanding notes payable were received from the Bermuda Lender and the maturity dates associated with these notes range from December 31, 2014 to May 7, 2015. Between January 17, 2014 and May 2, 2014, the Company issued Convertible Notes with an aggregate principal amount of $175,000, in consideration of $170,000 of new proceeds (a Convertible Note with a principal amount of $30,000 bears no interest and was issued for cash consideration of $25,000 and the $5,000 difference was recorded as debt discount and was accreted as interest over the term of the note resulting in a weighted average effective interest rate of 79%). Convertible Notes with an aggregate principal amount of $145,000 bear interest at a rate of 12% per annum payable upon maturity. The Convertible Notes were initially payable 3-12 months from the date of issuance. Of the $175,000 of Convertible Notes, $145,000 is convertible into shares of the Company's common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55%-60%, depending on the particular note, of the fair value of the Company's stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company's common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company's common stock, but with a floor of $0.05 per share. 11 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 5 - Notes Payable - Continued

During the six months ended June 30, 2014, the Company and certain lenders agreed to exchange notes payable with an aggregate principal balance of $274,000 and aggregate accrued interest of $19,932 for an aggregate of 1,101,453 shares of common stock and an immediately vested, two-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.75 per share. The stock and warrants had an aggregate issuance date value of $330,436 and $12,590, respectively, and, as a result, the Company recorded a loss on extinguishment of $49,094. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants. See Note 8 - Subsequent Events for details regarding additional note exchanges.



During the six months ended June 30, 2014, the Company elected to convert certain convertible notes payable with an aggregate principal balance of $100,000 and aggregate accrued interest of $6,187 into an aggregate of 442,778 shares of common stock at conversion prices ranging from $0.20 to $0.28 per share.

During the six months ended June 30, 2014, the holders of certain convertible notes elected to convert notes with an aggregate principal balance of $57,081 and aggregate accrued interest of $3,500 for an aggregate of 282,685 shares of common stock at conversion prices ranging from $0.20 to $0.22 per share.



During the six months ended June 30, 2014, the Company repaid certain notes payable with an aggregate principal balance of $53,000 and accrued interest of $11,219.

During the six months ended June 30, 2014, the maturity dates of certain notes payable with an aggregate principal balance of $752,500 and interest rates ranging from 8% to 15% per annum were extended from maturity dates ranging from August 8, 2013 to December 31, 2013 to new maturity dates ranging from March 1, 2014 to April 1, 2015. In connection with the extensions, (a) the amount of interest due at maturity for a certain note was increased to $35,000 from $20,000, (b) an aggregate $73,058 of accrued interest was converted into the principal balance of the certain notes, (c) immediately vested, five-year warrants to purchase an aggregate of 100,000 shares of common stock at an exercise price of $0.75 per share were issued to the lenders, (d) previously outstanding warrants to purchase an aggregate of 90,000 shares of common stock had their exercise prices reduced to $0.75 per share from exercise prices ranging from $1.75 to $2.50 per share and (e) in the event a certain note is not paid in full on or before maturity, the Company agreed to issue to the lender a five-year warrant to purchase 50,000 shares of common stock at an exercise price equal to 175% of the then fair market value of the Company's common stock. As of the filing date of this report, one of the extended notes was past due. During the six months ended June 30, 2014, the contingently adjustable conversion ratios associated with certain notes payable were resolved. The Company estimated the intrinsic value of the embedded conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company recognized the $41,384 intrinsic value related to these beneficial conversion features as debt discount and the entire amount was amortized during the three and six months ended June 30, 2014.



Note 6 - Commitments and Contingencies

Operating Lease On February 4, 2014, the Company and the landlord agreed to the surrender of a portion of the Jupiter, Florida leased premises and also extended the term of the lease to July 31, 2014. The amended lease provides for a base rent of $962 per month. On July 29, 2014, the Company and the landlord further amended the lease agreement such that, commencing on July 31, 2014, the lease shall automatically renew for successive three calendar month periods; provided, however, that both parties shall have the right to terminate the lease effective at the end of any such renewal term by providing written notice to the other party at least 30 days prior to the expiration of the applicable renewal term. On February 11, 2014, the Company executed a Facility Use Agreement with a stem cell treatment company ("SCTC") which permits the Company to utilize the SCTC's laboratory facility and one office for research associated with its culturing and medical device license. Payment terms are $3,750 through March 31, 2014 and $100 per day for usage beyond that date. 12 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 6 - Commitments and Contingencies - Continued

Operating Lease - Continued

Rent expense amounted to approximately $4,000 and $14,000 during the three and six months ended June 30, 2014, respectively, and $16,000 and $52,000 during the three and six months ended June 30, 2013, respectively. Rent expense is reflected in general and administrative expenses in the condensed consolidated statements of operations. Consulting Agreements

On February 20, 2014, the Company executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become the Company's Chief Medical Advisor for Spine Medicine pursuant to which he oversees the clinical aspects of the brtxDISC™ Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive $10,000 per month, escalating to $20,000 per month upon the FDA approval of the Company's Investigational New Drug or Investigational Device Exemption application with respect to its brtxDISC™ Program. In addition, the Company granted the consultant a five-year option to purchase 300,000 shares of common stock at an exercise price of $0.65 per share, pursuant to the Plan. The option vests ratably over three years on the grant date anniversaries and the grant date value of $67,830 will be recognized proportionate to the vesting period. On March 12, 2014, as additional compensation for consulting services, the Company granted to a consultant an immediately vested, five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.53 per share. In addition, warrants to purchase an aggregate of 280,000 shares of common stock had their exercise prices reduced to $0.53 per share from $1.50 per share and such warrants, as well as a warrant to purchase 20,000 shares of common stock, had their term extended to March 12, 2019. The grant date value of the issued warrant of $23,360 along with the incremental value related to the modification of the outstanding warrants of $30,366 was recognized during the six months ended June 30, 2014 as stock-based compensation expense, which is reflected as consulting expense in the condensed consolidated statements of operations. On March 14, 2014, the Company executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, the Company immediately granted the new Advisor a five-year option to purchase 25,000 shares of common stock at an exercise price of $0.50 per share, pursuant to the Plan. The option vests as follows: (i) 12,500 shares immediately and (ii) 12,500 shares on the first anniversary of the grant date. In addition, on each annual anniversary date of the agreement, the Advisor is entitled to a new five-year option to purchase 5,000 shares of the Company's common stock at an exercise price equal to the then fair market value of the common stock. The option grant date value of $5,860 will be recognized proportionate to the vesting period. On June 27, 2014, a February 17, 2011 agreement for marketing consulting services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and will continue in effect until December 31, 2014 (the "New Term"). In consideration of services rendered during the New Term and the cancellation of the Company's obligation to pay $65,000 to the consultant, the Company issued to a designee of the consultant 500,000 shares of common stock and issued to the consultant an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The common stock and warrant had grant date values of $110,000 and $37,500, respectively, which

were recognized immediately. On June 27, 2014, a February 17, 2011 agreement for business advisory services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and will continue in effect until December 31, 2014 (the "New Term"). In consideration of services rendered during the New Term, the Company agreed to pay a cash fee of $16,667 per month and the Company granted an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The warrant had a grant date value of $37,500 which was recognized immediately. 13 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 6 - Commitments and Contingencies - Continued

Consulting Agreements - Continued

On June 27, 2014, an August 16, 2012 agreement for scientific advisory services was further extended to August 16, 2016 such that the consultant will continue to serve as Chairman of the Company's Scientific Advisory Board, will earn $10,000 per month and will be entitled to specified expense reimbursements. In addition, the Company granted a ten-year option to purchase 300,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The option vests as follows: (i) 150,000 shares on August 16, 2015 and (ii) 150,000 shares on August 16, 2016. The option grant date value of $81,000 will be recognized proportionate to the vesting period.



During the six months ended June 30, 2014, the Company issued an aggregate of 378,458 additional shares of common stock valued at $130,398 to consultants pursuant to consulting agreements.

See Note 8 - Subsequent Events for details regarding an additional consulting agreement.

Research Agreement On May 9, 2014, the Company entered into an amendment to its Research Agreement, dated June 15, 2012, with the University of Utah (the "University") (the "Utah Agreement"). Pursuant to the amendment, the parties agreed that (i) no fees are payable by the Company to the University pursuant to the Utah Agreement for the first five monthly payments in 2014 ($208,335 of fees in total were cancelled, of which, $104,168 was accrued for as of March 31, 2014), (ii) effective with the payment due on June 15, 2014, the monthly fee payable by the Company to the University pursuant to the Utah Agreement will be reduced from $41,667 to $20,000 and (iii) the scope of the work to be performed by the University pursuant to the Utah Agreement will be reduced. The Utah Agreement is scheduled to expire on June 14, 2015. Concurrently with the execution of the amendment, the Company paid $323,336 to the University, representing the balance of all fees payable by the Company to date pursuant to the Utah Agreement. As a result, the Company recorded a gain on settlement in the amount of $166,668 during the three and six months ended June 30, 2014. Board of Directors

On June 27, 2014, a director of the Company resigned due to other business commitments. In consideration of director services performed to date, the Company agreed to pay an aggregate of $80,000 (of which, $50,000 was previously earned and accrued for), payable as follows: (i) $30,000 immediately and (ii) the $50,000 balance in six equal monthly installments commencing on July 31, 2014. In addition, all outstanding options held by the director which were not exercisable as of the date of resignation shall become exercisable on the earlier of (i) the date on which such options are scheduled to become exercisable or (ii) December 31, 2014, and all outstanding options shall remain exercisable until their respective expiration dates notwithstanding the director's resignation. As a result of the modification of the options, the Company recorded incremental stock-based compensation expense of $96,250. On June 27, 2014, the Company elected two new directors. Concurrently with the election, the Company granted the directors ten-year options to purchase an aggregate of 600,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The options vest as follows: (i) an aggregate of 200,000 shares on the date of grant; (ii) an aggregate of 200,000 shares on the first anniversary of the date of grant; and (iii) an aggregate of 200,000 shares on the second anniversary of the date of grant. The options have an aggregate grant date value of $144,000 which will be recognized proportionate to the

vesting period. Claims In November 2013, an action was commenced in the Circuit Court of Palm Beach County, Florida by an alleged former consultant against the Company. The action is associated with an alleged loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff is seeking to recover an unspecified amount of damages but at least approximately $193,000 of cash and warrants for the purchase of 80,000 shares of the Company's common stock. During March 2014, the Company filed its answer to the complaint wherein it denied the allegations and entered thirteen affirmative defenses. Procedural hearings commenced in July 2014. The Company has not accrued for a loss associated with this matter as it believes that the claims are without merit and it intends to vigorously defend this matter.



The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

14 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 7 - Stockholders' Deficiency

2010 Equity Participation Plan

On February 18, 2014, the Board of Directors of the Company approved an increase in the number of shares of common stock authorized to be issued pursuant to the Plan from 6,000,000 to 12,000,000.



Common Stock and Warrant Offerings

During the six months ended June 30, 2014, the Company issued an aggregate of 2,968,651 shares of common stock at prices ranging from $0.25 to $0.45 per unit to investors for aggregate gross proceeds of $945,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 729,861 shares of common stock with exercise prices ranging from $0.30 to $0.75 per share. The warrants have terms ranging from two to five years. See Note 5 - Notes Payable for details associated with common stock issued in conjunction with the conversion and exchange of notes payable. See Note 6 - Commitments and Contingencies - Consulting Agreements for details associated with common stock issued pursuant to consulting agreements. See Note 7 - Stockholders' Deficiency - Warrant Exchange and Reload Program for details associated with common stock issued pursuant to warrant exercises. See Note 8 - Subsequent Events for details regarding additional issuances of common stock and warrants for cash.



Warrant and Option Valuation

The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at annual rates ranging from 0% to 5% for options granted during the six months ended June 30, 2014. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the "simplified" method to develop an estimate of the expected term of "plain vanilla" employee option grants. Since the Company's stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.



Warrant Exercise and Reload Program

On November 27, 2013, the Company initiated a limited time program (the "Warrant Exercise and Reload Program") which, at the election of any warrant holder, would permit them to immediately exercise their outstanding exercisable warrants at an exercise price of $0.30 per share. In connection with the exercise of the warrant, in addition to having received the number of shares pursuant to such exercise, each holder would receive a new warrant for the same number of shares purchased with an exercise price of $0.75 per share and an expiration date of December 31, 2015. The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days. Under the Warrant Exercise and Reload Program, warrants to purchase an aggregate of 266,667 shares of common stock were exercised during the six months ended June 30, 2014 for aggregate gross proceeds of $80,000. The Company recognized a warrant modification charge of $0 and $30,128 during the three and six months ended June 30, 2014, respectively, which represents the incremental value of the modified warrant and new warrant combined, as compared to the original warrant value, all valued as of the respective modification dates. Stock Warrants See Note 5 - Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 6 - Commitments and Contingencies - Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 7 - Stockholders' Deficiency - Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings. See Note 8 - Subsequent Events for details associated with the issuance of warrants as compensation. 15 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 7 - Stockholders' Deficiency - Continued

Stock Warrants - Continued



In applying the Black-Scholes option pricing model to warrants granted, the Company used the following weighted average assumptions:

For the Three Months Ended For the Six Months Ended June 30, June 30, 2014 2013 2014 2013 Risk free interest rate 1.64 % 0.93 % 1.58 % 0.81 % Expected term (years) 5.00 5.00 4.78 4.98 Expected volatility 120 % 135 % 120 % 135 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2014 was $0.16 and $0.19 per share, respectively. The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2013 was $0.36 and $0.63 per share, respectively. The Company recorded stock-based compensation expense of $113,400 and $167,126 during the three and six months ended June 30, 2014, respectively, and a credit of $3,596 and expense of $20,604 during the three and six months ended June 30, 2013, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the condensed consolidated statements of operations. As of June 30, 2014, there was no unrecognized stock-based compensation expense related to stock warrants. A summary of the stock warrant activity during the six months ended June 30, 2014 is presented below: Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2013 4,795,890 $ 1.39 Granted 1,796,528 0.74 Exercised (266,667 ) 0.30 [1] Forfeited - - Outstanding, June 30, 2014 6,325,751 $ 1.05 3.2 $ - Exercisable, June 30, 2014 5,625,751 $ 0.99 3.2 $ - 16 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 7 - Stockholders' Deficiency - Continued

Stock Warrants - Continued The following table presents information related to stock warrants at June 30, 2014: Warrants Outstanding Warrants Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 0.30 650,000 4.9 650,000 0.50 40,000 0.1 40,000 0.53 380,000 3.9 380,000 0.75 2,632,557 2.3 2,632,557 0.94 50,000 4.4 50,000 1.00 550,000 4.9 550,000 1.50 862,800 3.0 862,800 1.75 70,000 3.6 70,000 2.00 123,530 4.4 123,530 2.50 60,000 3.0 60,000 3.00 36,864 3.8 36,864 4.00 170,000 3.6 170,000 Variable [2] 700,000 - - 6,325,751 3.2 5,625,751



[1] Warrants to purchase an aggregate of 266,667 shares of common stock had their

exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise

and Reload Program. The warrants previously had exercise prices that ranged

from $1.50 to $4.00 per share. See Note 7 - Stockholders' Deficiency - Warrant Exercise and Reload Program.



[2] Warrants to purchase 700,000 shares of common stock have an exercise price

which is the greater of $1.50 per share or the fair market value of the

common stock on the date certain performance criteria are met. Exercisability

of warrants is subject to satisfaction of certain performance criteria which

did not occur during the six months ended June 30, 2014. Stock Options



See Note 6 - Commitments and Contingencies for details associated with the issuance and modification of options to consultants and directors.

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:

For the Three Months Ended For the Six Months Ended June 30, June 30, 2014 2013 2014 2013 Risk free interest rate 1.93 % 1.13 % 1.61 % 1.81 % Expected term (years) 6.88 5.00 5.81 9.62 Expected volatility 120 % 135 % 120 % 135 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % 17 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 7 - Stockholders' Deficiency - Continued

Stock Options - Continued



The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2014 was $0.25 and $0.24 per share, respectively. The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2013 was $0.41 and $0.74 per share, respectively.

Between February 18, 2014 and March 12, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 2,415,000 shares of common stock at exercise prices ranging from $0.53 to $0.65 per share, pursuant to the Plan. The shares vest as follows: (i) 831,669 shares immediately and (ii) 1,589,331 shares ratably over two years on the grant date anniversaries. The aggregate grant date value of $566,483 will be recognized proportionate to the vesting period. On June 16, 2014, the Company granted a five-year option to a consultant to purchase 60,000 shares of common stock at an exercise price of $0.39 per share, pursuant to the Plan. The shares vest ratably over three months on the grant date anniversaries. The grant date value of $18,600 will be recognized proportionate to the vesting period.



The following table presents information related to stock option expense:

Weighted Average For The Three Months Ended For The Six Months Ended Unrecognized Amortization June 30, June 30, at June 30, Period 2014 2013 2014 2013 2014 (Years) Consulting $ 150,962$ 19,125$ 251,575$ 64,250$ 166,128 [1] 1.8 Research and development 32,324 40,127 153,714 123,859 193,573 [2] 1.8 General and administrative 21,280 52,681 104,979 106,431 151,659 1.6 $ 204,566$ 111,933$ 510,268$ 294,540$ 511,360 1.8



[1] Includes $8,363 of unrecognized expense that is subject to non-employee

mark-to-market adjustments.

[2] Includes $152,710 of unrecognized expense that is subject to non-employee

mark-to-market adjustments. A summary of the stock option activity during the six months ended June 30, 2014 is presented below: Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2013 5,043,000 $ 1.03 Granted 3,700,000 0.55 Exercised - - Forfeited (34,000 ) 1.31 Outstanding, June 30, 2014 8,709,000 $ 0.83 8.4 $ 13,500 Exercisable, June 30, 2014 5,323,167 $ 0.97 7.4 $ 3,000 18 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited)



Note 7 - Stockholders' Deficiency - Continued

Stock Options - Continued The following table presents information related to stock options at June 30, 2014: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.285 900,000 10.0 200,000 0.390 60,000 - - 0.500 345,000 5.4 332,500 0.530 40,000 9.7 40,000 0.600 980,000 9.3 490,000 0.650 2,675,000 5.6 791,667 1.000 131,000 8.1 81,000 1.050 2,270,000 7.6 2,270,000 1.100 5,000 2.9 5,000 1.200 10,000 1.9 10,000 1.250 43,000 2.4 43,000 1.400 350,000 5.4 160,000 1.500 900,000 8.4 900,000 8,709,000 7.4 5,323,167 Common Stock Awards



See Note 8 - Subsequent Events for details associated with the issuance of common stock as consultant compensation.

The following table presents information related to common stock award expense: For The Three Months Ended For The Six Months Ended Unrecognized June 30, June 30, at June 30, 2014 2013 2014 2013 2014 Consulting $ 224,500$ 6,001$ 234,500$ 54,001 $ - Research and development 1,827 - 5,898 723 - General and administrative - - - - - $ 226,327$ 6,001$ 240,398$ 54,724 $ - A summary of common stock award activity for the six months ended June 30, 2014 is presented below: Weighted Average Total Number of Grant Date Grant Date Shares Fair Value Fair Value Non-vested, December 31, 2013 - $ - $ - Granted 878,458 0.27 240,398 Vested (878,458 ) (0.27 ) (240,398 ) Forfeited - - - Non-vested, June 30, 2014 - $ - $ - 19 | Page BIORESTORATIVE THERAPIES, INC. & SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (unaudited) Note 8 - Subsequent Events Consulting Agreement On July 23, 2014, the Company entered into a one-year agreement with a consultant to provide services related to the introduction to potential strategic partners and other alliance candidates with regard to research and development arrangements and other business transactions. In exchange for services provided by the consultant during the term, the Company agreed to issue 30,000 shares of common stock of the Company for each complete month during

the term. Notes Payable

On July 15, 2014, the Company received $89,063 pursuant to the research and development agreements discussed in Note 3 - Summary of Significant Accounting Policies - Revenue Recognition - Research and Development Agreements which triggered the mandatory principal prepayment of $89,063 of the note payable that was issued to the Bermuda Lender on May 8, 2014. As of the filing date of this report, the mandatory prepayment was unpaid. On or about August 13, 2014, Cayman and the Bermuda Lender agreed to extend the maturity date of certain notes issued by Cayman to the Bermuda Lender in the aggregate principal amount of $4,000,000 from July 31, 2014 to December 31, 2014. In consideration of the extension, the Company issued to the Bermuda Lender 550,000 shares of common stock.



Subsequent to June 30, 2014, the Company and certain lenders agreed to exchange notes payable with an aggregate principal balance of $76,669 and aggregate accrued interest of $2,992 for an aggregate of 489,505 shares of common stock.

Common Stock and Warrant Offerings

Subsequent to June 30, 2014, the Company issued an aggregate of 703,333 shares of common stock at prices ranging from $0.25 to $0.30 per unit to investors for aggregate gross proceeds of $205,000. In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 175,833 shares of common stock at an exercise price of $0.75 per share. Stock-Based Compensation



Subsequent to June 30, 2014, the Company issued an aggregate of 45,273 shares of common stock to consultants pursuant to consulting agreements.

Subsequent to June 30, 2014, the Company issued to a consultant an immediately vested five-year warrant to purchase 10,000 shares of the Company's common stock at an exercise price of $0.75 per share. 20 | Page



Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the results of operations and financial condition of BioRestorative Therapies, Inc. (and including its subsidiaries, "BRT") as of June 30, 2014 and December 31, 2013 and for the three and six months ended June 30, 2014 and 2013 should be read in conjunction with our financial statements and the notes to those financial statements that are included elsewhere in this Quarterly Report on Form 10-Q. References in this Management's Discussion and Analysis of Financial Condition and Results of Operations to "us," "we," "our," and similar terms refer to BRT. This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions, are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based. Factors that may affect our results include, but are not limited to, the risks and uncertainties discussed in Item 7 ("Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors That May Affect Results and Financial Condition") of our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC") on April

11, 2014.



Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

Overview Our goal is to develop technology using cell and tissue regenerative therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, we intend to focus on the unity of medical and scientific explanations for future clinical procedures and outcomes and the provision of adult stem cells for future personal medical applications. Among the initiatives that we are currently pursuing is our brtxDISC™ (Disc Implanted Stem Cells) Program. We have obtained a license that permits us to use technology for adult stem cell treatment of disc and spine conditions, including protruding, bulging and herniated discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the legs and feet. Another technology we are developing is our ThermoStem® Program. This pre-clinical program involves the use of brown fat in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies. We also offer stem cell derived cosmetic and skin care products. Pursuant to our brtx-C Cosmetic Program, we have developed an ingredient derived from human adult stem cells which can be used by third party companies in the development of their own skin care products. Separately, through our wholly-owned subsidiary, Stem Pearls, LLC, we offer facial creams and other skin care products with certain ingredients that may include plant stem cells and/or other plant derived stem cell optimization or regenerative compounds. We currently are seeking to establish a new laboratory facility and increase our capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. As of June 30, 2014, our accumulated deficit was $22,815,229, our stockholders' deficiency was $7,148,786 and our working capital deficiency was $8,163,102. While we have recently begun to generate a modest amount of revenue, our losses have principally been operating expenses incurred in research and development, marketing and promotional activities in order to commercialize our products and services, plus costs associated with meeting the requirements of being a public company. We expect to continue to incur substantial costs for these activities over at least the next year. 21 | Page Based upon our working capital deficiency as of June 30, 2014 and our forecast for continued operating losses, we require equity and/or debt financing to continue our operations. As of June 30, 2014, our outstanding debt of $6,029,727, together with interest at stated rates ranging between 8% and 15% per annum, was due on various dates through May 2015. Subsequent to June 30, 2014 and through August 14, 2014, we have received aggregate equity financing of $205,000, we have received research and development payments of $89,063, the due date for the repayment of $4,000,000 of debt has been extended, and $76,669 and $2,992 of debt and accrued interest, respectively, has been exchanged for common stock. Giving effect to the above actions, we currently have notes payable aggregating $244,063 which are either past due or payable on demand. Based upon our working capital deficiency and outstanding debt, we expect to be able to fund our operations through October 2014. We are currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. We are currently considering several different financing alternatives to support our operations thereafter. If we are unable to obtain such additional financing on a timely basis and, notwithstanding any request we may make, our debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, we may have to curtail our development, marketing and promotional activities, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations and liquidate. See "Liquidity and Capital Resources" below. Recent Developments



Research and Development Agreements

On March 19, 2014, we entered into a one-year research and development agreement with a Japanese pharmaceutical company. Pursuant to the agreement, we have been engaged to provide research and development services with regard to stem cells. The agreement provides for an initial payment to us of $150,000 (which was received in March 2014) and the payment of up to an additional $100,000, subject to the achievement of specified deliverables. On March 24, 2014, we entered into a research agreement with a U.S. pharmaceutical company. Pursuant to the agreement, we have been engaged to provide research and development services with regard to brown fat. The agreement provides for an initial payment to us of $250,000 (which was received in April 2014) and the payment of up to an additional $525,000 during the two year term of the agreement.



Medical and Scientific Advisory

On February 20, 2014, we executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become our Chief Medical Advisor for Spine Medicine pursuant to where he has assumed responsibility for the clinical aspects of the brtxDISC™ Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive $10,000 per month, escalating to $20,000 per month upon the FDA approval of our Investigational New Drug or Investigational Device Exemption application with respect to our brtxDISC™ Program. In addition, we granted a five-year option to purchase 300,000 shares of common stock at an exercise price of $0.65 per share, pursuant to our 2010 Equity Participation Plan (the "Plan"). The option vests ratably over three years on the grant date anniversaries. On March 14, 2014, we executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, we immediately granted the new Advisor a five-year option to purchase 25,000 shares of common stock at an exercise price of $0.50 per share, pursuant to the Plan. The option vests as follows: (i) 12,500 shares immediately and (ii) 12,500 shares on the first anniversary of the grant date. In addition, on each annual anniversary date of the agreement, the Advisor is entitled to a new five-year option to purchase 5,000 shares of our common stock at an exercise price equal to the then fair market value of the common stock. Board of Directors



On June 27, 2014, Joel San Antonio resigned from our Board of Directors due to other business commitments.

On June 27, 2014, Paul Jude Tonna was elected to our Board of Directors. Mr. Tonna was appointed as a member of the Audit Committee, the Compensation Committee and the Nominating Committee of the Board. Concurrent with his election, Mr. Tonna was granted an option to purchase 300,000 shares of our common stock at an exercise price of $0.285 per share pursuant to the Plan. The option vests to the extent of 100,000 shares on the date of grant, 100,000 shares on the first anniversary of the date of grant and 100,000 shares on the second anniversary of the date of grant and is exercisable for a period of ten years, subject to the provisions of the Plan. 22 | Page

On June 27, 2014, Joseph B. Swiader was elected to our Board of Directors. Mr. Swiader was appointed as a member of the Compensation Committee and the Nominating Committee of the Board. Concurrently with his election, Mr. Swiader was granted an option to purchase 300,000 shares of our common stock at an exercise price of $0.285 per share pursuant to the Plan. The option vests to the extent of 100,000 shares on the date of grant, 100,000 shares on the first anniversary of the date of grant and 100,000 shares on the second anniversary of the date of grant and is exercisable for a period of ten years, subject to

the provisions of the Plan.



Consolidated Results of Operations

Three Months Ended June 30, 2014Compared With Three Months Ended June 30, 2013

The following table presents selected items in our unaudited condensed consolidated statements of operations for the three months ended June 30, 2014 and 2013, respectively: For The Three Months Ended June 30, 2014 2013 Revenues $ 175,941$ 425 Cost of sales 42,366 36 Gross Profit 133,575 389 Operating Expenses Marketing and promotion 15,535 35,711 Consulting 557,565 140,389 Research and development 293,330 372,916 General and administrative 548,632 565,251 Total Operating Expenses 1,415,062 1,114,267 Loss From Operations (1,281,487 ) (1,113,878 ) Other (Expense) Income Interest expense (72,390 ) (32,035 )



Amortization of debt discount (145,930 ) (105,282 ) Gain on settlement of payables 166,668

- Total Other Expense (51,652 ) (137,317 ) Net Loss $ (1,333,139 )$ (1,251,195 ) Gross profit

For the three months ended June 30, 2014, we generated $175,025 of revenues through the services provided pursuant to our research and development agreements and $916 of sales of Stem Pearls® skincare products. For the three months ended June 30, 2013, revenues consisted only of $425 of sales of Stem Pearls® skincare products. Cost of sales For the three months ended June 30, 2014, cost of sales was $42,366 as compared to $36 for the comparable 2013 period. For the three months ended June 30, 2014, cost of sales consisted primarily of $42,251 of costs related to our research and development agreements. For the three months ended June 30, 2013, cost of sales consisted of the costs of the underlying Stem Pearls® skincare products. 23 | Page Marketing and promotion Marketing and promotion expenses include advertising and promotion, marketing and seminars, meals, and entertainment and travel expenses. For the three months ended June 30, 2014, marketing and promotion expenses decreased by $20,176, or 56%, to $15,535 from $35,711 in the comparable 2013 period. We expect that marketing and promotion expenses will increase in the future as we increase our marketing activities following full commercialization of our products and services. Consulting

Consulting expenses consist of consulting fees and stock-based compensation to consultants. For the three months ended June 30, 2014, consulting expenses increased $417,176, or 297%, to $557,565 from $140,389 in the comparable 2013 period. The increase is primarily due to an approximate $468,000 increase in non-cash stock-based compensation to directors, consultants and advisors and an approximate increase of $20,000 in directors fees related to the resignation of one the members of our Board of Directors whereby we agreed to pay the director for the remainder of his 2014 compensation, partially offset by an approximate $72,000 of reduction in cash consulting fees. Research and development

Research and development expenses include cash and non-cash compensation of (a) our Chief Executive Officer (in part); (b) our Vice President of Research and Development; and (c) our Scientific Advisory Board members, and costs related to our brown fat and disc/spine initiatives. Research and development expenses are expensed as they are incurred. For the three months ended June 30, 2014, research and development expenses decreased by $79,586, or 21%, to $293,330 from $372,916 in the comparable 2013 period. The decrease is primarily related to the amendment of our University of Utah Research Agreement resulting in a reduction of expense related to our brown fat and disc/spine initiatives as compared to the prior period of approximately $40,000.



We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.

General and administrative

General and administrative expenses consist primarily of salaries, bonuses, payroll taxes, severance costs and stock-based compensation to employees (excluding any cash or non-cash compensation of (a) our Chief Executive Officer attributable to research and development and (b) our Vice President of Research and Development) as well as corporate support expenses such as legal and professional fees, investor relations and occupancy related expenses. For the three months ended June 30, 2014, general and administrative expenses decreased by $16,619, or 3%, to $548,632 from $565,251 in the comparable 2013 period.



We expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional costs to support the growth of our business.

Interest expense For the three months ended June 30, 2014, interest expense increased $40,355, or 126%, to $72,390 from $32,035 in the comparable 2013 period. The increase was due to increased interest-bearing outstanding short-term borrowings as compared to the second quarter of 2013.



Amortization of debt discount

For the three months ended June 30, 2014, amortization of debt discount increased by $40,648, or 39%, to $145,930 from $105,282 in the comparable 2013 period. The increase was primarily due to the recognition of expense related to the beneficial conversion features of convertible notes and the timing of the recognition of the debt discount expense. 24 | Page



Gain on settlement of payables

For the three months ended June 30, 2014, we recognized a gain on settlement of payables of $166,668 related to the amendment of our University of Utah Research Agreement regarding our brown fat and disc/spine initiatives whereby a portion of the fees payable to the University of Utah were cancelled. Six Months Ended June 30, 2014 Compared With Six Months Ended June 30, 2013 The following table presents selected items in our unaudited condensed consolidated statements of operations for the six months ended June 30, 2014 and 2013, respectively: For The Six Months Ended June 30, 2014 2013 Revenues $ 176,316$ 1,555 Cost of sales 42,426 198 Gross Profit 133,890 1,357 Operating Expenses Marketing and promotion 47,329 65,592 Consulting 824,763 370,505 Research and development 787,071 773,358 General and administrative 1,184,632 1,205,361 Total Operating Expenses 2,843,795 2,414,816 Loss From Operations (2,709,905 ) (2,413,459 ) Other (Expense) Income Interest expense (145,521 ) (229,903 ) Amortization of debt discount (244,435 ) (166,631 ) Loss on extinguishment of notes payable, net (49,094 ) (7,200 ) Warrant modification expense (30,128 ) - Gain on settlement of payables 176,268

- Total Other Expense (292,910 ) (403,734 ) Net Loss $ (3,002,815 )$ (2,817,193 ) Gross profit For the six months ended June 30, 2014, we generated $175,025 of revenues through the services provided pursuant to our research and development agreements and $1,291 of sales of Stem Pearls® skincare products. For the six months ended June 30, 2013, revenues consisted only of $1,555 of sales of Stem Pearls® skincare products. Cost of sales For the six months ended June 30, 2014, cost of sales was $42,426 as compared to $198 for the comparable 2013 period. For the six months ended June 30, 2014, cost of sales consisted primarily of $42,251 of costs related to our research and development agreements. For the six months ended June 30, 2013, cost of sales consisted of the costs of the underlying Stem Pearls® skincare products. 25 | Page Marketing and promotion Marketing and promotion expenses include advertising and promotion, marketing and seminars, meals, and entertainment and travel expenses. For the six months ended June 30, 2014, marketing and promotion expenses decreased by $18,263, or 28%, to $47,329 from $65,592 in the comparable 2013 period. We expect that marketing and promotion expenses will increase in the future as we increase our marketing activities following full commercialization of our products and services. Consulting

Consulting expenses consist of consulting fees and stock-based compensation to consultants. For the six months ended June 30, 2014, consulting expenses increased $454,258, or 123%, to $824,763 from $370,505 in the comparable 2013 period. The increase is primarily due to an approximate $514,000 increase in non-cash stock-based compensation to directors, consultants and advisors and an approximate increase of $20,000 in directors fees related to the resignation of one the members of our Board of Directors whereby we agreed to pay the director for the remainder of his 2014 compensation, partially offset by an approximate $81,000 of reduction of cash consulting fees. Research and development

Research and development expenses include cash and non-cash compensation of (a) our Chief Executive Officer (in part); (b) our Vice President of Research and Development; and (c) our Scientific Advisory Board members, and costs related to our brown fat and disc/spine initiatives. Research and development expenses are expensed as they are incurred. For the six months ended June 30, 2014, research and development expenses increased by $13,713, or 2%, to $787,071 from $773,358 in the comparable 2013 period.



We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.

General and administrative

General and administrative expenses consist primarily of salaries, bonuses, payroll taxes, severance costs and stock-based compensation to employees (excluding any cash or non-cash compensation of (a) our Chief Executive Officer attributable to research and development and (b) our Vice President of Research and Development) as well as corporate support expenses such as legal and professional fees, investor relations and occupancy related expenses. For the six months ended June 30, 2014, general and administrative expenses decreased by $20,729, or 2%, to $1,184,632 from $1,205,361 in the comparable 2013 period.



We expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional costs to support the growth of our business.

Interest expense

For the six months ended June 30, 2014, interest expense decreased $84,382, or 37%, to $145,521 from $229,903 in the comparable 2013 period. The decrease was due to reduced interest-bearing outstanding short-term borrowings as compared to the comparable 2013 period.



Amortization of debt discount

For the six months ended June 30, 2014, amortization of debt discount increased by $77,804, or 47%, to $244,435 from $166,631 in the comparable 2013 period. The increase was primarily due to the recognition of expense related to the beneficial conversion features of convertible notes and the timing of the recognition of the debt discount expense.



Loss on extinguishment of notes payable, net

For the six months ended June 30, 2014, we recorded a net loss on extinguishment of notes payable of $49,094, which is associated with investors' exchange of debt for equity securities, as compared to a net loss on extinguishment of notes payable of $7,200 for the comparable 2013 period. 26 | Page



Warrant modification expense

For the six months ended June 30, 2014, we recorded expense of $30,128 related to the modification of outstanding investor warrants.

Gain on settlement of payables

For the six months ended June 30, 2014, we recognized a gain on settlement of payables of $176,268 primarily related to the amendment of our University of Utah Research Agreement regarding our brown fat and disc/spine initiatives whereby a portion of the fees payable to the University of Utah were cancelled.



Liquidity and Capital Resources

Liquidity



We measure our liquidity in a number of ways, including the following:

June 30, December 31, 2014 2013 (unaudited) Cash $ 59,163$ 201,098



Working Capital Deficiency $ (8,163,102 )$ (7,262,748 ) Notes Payable (Gross - Current) $ 5,953,058$ 5,754,500

Availability of Additional Funds

Based upon our working capital deficiency and stockholders' deficiency of $8,163,102 and $7,148,786, respectively, as of June 30, 2014, we require additional equity and/or debt financing to continue our operations. These conditions raise substantial doubt about our ability to continue as a going concern.

As of June 30, 2014, our outstanding debt of $6,029,727, together with interest at stated rates ranging between 8% and 15% per annum, was due on various dates through May 2015. Subsequent to June 30, 2014 and through August 14, 2014, we have received aggregate equity financing of $205,000, we have received research and development payments of $89,063, the due date for the repayment of $4,000,000 of debt has been extended, and $76,669 and $2,992 of debt and accrued interest, respectively, has been exchanged for common stock. Giving effect to the above actions, we currently have notes payable aggregating $244,063 which are either past due or payable on demand. As of the date of filing, our outstanding debt was as follows: Principal Maturity Date Amount Past Due/On Demand $ 244,063 QE 9/30/14 285,000 QE 12/31/14 4,672,685 QE 3/31/15 50,000 QE 6/30/15 693,810 $ 5,945,558 27 | Page Based upon our working capital deficiency, outstanding debt and forecast for continued operating losses we expect that the cash we currently have available will fund our operations through October 2014. Thereafter, we will need to raise further capital, through the sale of additional equity or debt securities, to support our future operations and to repay our debt (unless, if requested, the debt holders agree to convert their notes into equity or extend the maturity dates of their notes). Our operating needs include the planned costs to operate our business, including amounts required to fund working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings.

We may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Debt financing may require us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further indebtedness, and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing agreements on unattractive terms.

Our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate our continuation as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome

of this uncertainty.



During the six months ended June 30, 2014 and 2013, our sources and uses of cash were as follows:

Net Cash Used in Operating Activities

We experienced negative cash flow from operating activities for the six months ended June 30, 2014 and 2013 in the amounts of $1,759,925 and $1,474,259, respectively. The net cash used in operating activities for the six months ended June 30, 2014 was primarily due to cash used to fund a net loss of $3,002,815, adjusted for net non-cash expenses in the aggregate amount of $1,116,329 partially offset by $126,561 of net cash provided by changes in the levels of operating assets and liabilities, primarily as a result of increases in accrued interest, expenses and other current liabilities and deferred revenues. The net cash used in operating activities for the six months ended June 30, 2013 was primarily due to cash used to fund a net loss of $2,817,193, adjusted for non-cash expenses in the aggregate amount of $596,804 partially offset by $746,130 of net cash provided primarily as a result of increases in accounts payable plus accrued expenses and other current liabilities, due to cash constraints during the period.



Net Cash Provided by Investing Activities

During the six months ended June 30, 2014, $980 of cash was provided by proceeds received from the sale of fixed assets. During the six months ended June 30, 2013, no cash was provided by investing activities.



Net Cash Provided by Financing Activities

Net cash provided by financing activities during the six months ended June 30, 2014 and 2013 was $1,617,010 and $1,474,015, respectively. During the six months ended June 30, 2014, $592,010 of net proceeds were from debt financings and $1,025,000 of proceeds were from equity financings (including proceeds received in connection with the exercise of common stock purchase warrants). During the six months ended June 30, 2013, $905,000 of proceeds were from equity financings and $569,015 of proceeds were from debt financings.



Critical Accounting Policies and Estimates

There are no material changes from the critical accounting policies set forth in "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission on April 11, 2014, except as disclosed below. Please refer to that document for disclosures regarding the critical accounting policies related to our business. 28 | Page



Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers," ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. We are currently evaluating the impact of the adoption of ASU 2014-09on our condensed consolidated financial position and results of operations. In June 2014, the FASB issued ASU No. 2014-10, "Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation," ("ASU 2014-10"). ASU 2014-10 removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders' equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. We have elected to adopt ASU 2014-10 effective with this Quarterly Report on Form 10-Q and its adoption resulted in the removal of previously required development stage disclosures. In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We do not anticipate that the adoption of ASU 2014-12 will have a material impact on our condensed consolidated financial statements.



Off-Balance Sheet Arrangements

None.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters